Breaking News
Black Friday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Atara Biotherapeutics Inc (ATRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Atara Biotherapeutics Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
17.57 -0.58    -3.20%
26/11 - Closed. Currency in USD ( Disclaimer )
After Hours
17.57
-0.04
-0.23%
13:32:27 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US0465131078 
CUSIP:  046513107
  • Volume: 414,324
  • Bid/Ask: 16.00 / 18.48
  • Day's Range: 17.03 - 18.07
Atara Biotherapeutics Inc 17.57 -0.58 -3.20%
Latest Release

Nov 04, 2021

EPS / Forecast

-0.9 / -0.9021

Revenue / Forecast

5.37M / 4.55M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Mar 03, 2022 12/2021 -- /  -0.7384 -- /  24.76M
Nov 04, 2021 09/2021 -0.9 /  -0.9021 5.37M /  4.55M
Aug 09, 2021 06/2021 -0.91 /  -0.8728 3.87M /  4.95M
May 04, 2021 03/2021 -0.86 /  -0.9013 3.55M /  2.05M
Mar 01, 2021 12/2020 -0.95 /  -0.7464 0.00 /  0.00
Nov 09, 2020 09/2020 -0.92 /  -1.09 0.00 /  0.00
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATRA Comments

Write your thoughts about Atara Biotherapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Павел Толстых
Павел Толстых 18 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BRIEF-Atara Biotherapeutics - Entered Into Sales Agreement For Offering Of Up To $100 MillionNov 26 (Reuters) - Atara Biotherapeutics Inc:* ATARA BIOTHERAPEUTICS - ENTERED INTO SALES AGREEMENT FOR OFFERING OF UP TO $100 MILLION
Nguyen Anh
Nguyen Anh Nov 14, 2021 3:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
trash ?
Edward Quiwitt
Edward Quiwitt Sep 01, 2021 10:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
End of 3Q but there are no something in FDA calendar?
Edward Quiwitt
Edward Quiwitt Sep 01, 2021 10:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Insider Joe Newell Sell 3,500 shares worth $52,500.00 ($15.00 Average Share Price)
Edward Quiwitt
Edward Quiwitt Aug 30, 2021 9:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Citigroup Downgrades Atara Biotherapeutics, Inc. (ATRA) to $23 from $27
Pavel Pavlov
Pavel Pavlov Dec 09, 2020 10:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What has happened to ATRA?
Pavel Pavlov
Pavel Pavlov Dec 09, 2020 10:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What has happened to ATRA?
Vit Pit
Vit Pit Dec 09, 2020 10:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Issues more stocks
Pavel Pavlov
Pavel Pavlov Dec 09, 2020 10:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what has happened?
Small Data
Small Data Dec 07, 2020 4:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🔥Requires reading! Bayer pays Atara bio $ atra an advance of $ 60mil and potentially $ 600 mil + royalties with a percentage of future sales towards its target Mesothelin. They enter into strategic partnerships 🚀🔥 - we are waiting for the opening of 🇷🇺 our session and the US session 🇺🇸. There should be a jerk up 🚀, pumps and gaps with closure are possible.
Episcopolian OptionTrader
Episcopolian1 Jan 02, 2018 10:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
According to IR, $ATRA won't be issuing secondary any time soon. Possibly after the successful Phase 3 test.. It's a BUY!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email